CD8A and systemic lupus erythematosus: pCons peptide therapy induces immune tolerance by promoting expansion of CD8+ and CD4+ Tregs.[9,10,22,25,27,28,53,56] pCons-induced Tregs suppress the production of anti-dsDNA autoantibodies, reduce proteinuria, and delay nephritis in murine lupus.[22,53] Notably, oral administration of different forms of pCons peptide, including D and L forms, delayed anti-ds-DNA Ab production and lupus nephritis, and increased the survival of lupus mice.[57]